Biosimilars Have Driven Down Cost of Infliximab
Biosimilars have driven down the costs of originator biologics, but it isn't clear whether those savings are being passed on to patients or increasing access to the drugs.
Stay updated with breaking news from Colitis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biosimilars have driven down the costs of originator biologics, but it isn't clear whether those savings are being passed on to patients or increasing access to the drugs.
While I knew from the title page that Gut Reaction had two authors, I did not know they were next-door neighbors, not to mention mother (Kirby Larson) and daughter (Quinn Wyatt)! Kirby and Quinn collaborated on this novel about a middle schooler, Tess, who at first suffers alone with an embarrassing, painful, and debilitating condition that she (along with readers) comes to understand is Crohn’s disease, an illness Quinn knows firsthand.
In the treatment of IBD, combinations of biologics or a biologic and tofacitinib appeared to be generally safe and effective, according to a new systematic review and meta-analysis.
Bruce Sands, MD, MS.,Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenter...
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...